Oral erythema multiforme after Pfizer-BioNTech COVID-19 vaccination: a report of four cases.
Adverse reaction
BioNTech/Pfizer
Case report
Covid-19 vaccine
Erythema multiforme
Journal
BMC oral health
ISSN: 1472-6831
Titre abrégé: BMC Oral Health
Pays: England
ID NLM: 101088684
Informations de publication
Date de publication:
24 03 2022
24 03 2022
Historique:
received:
27
10
2021
accepted:
16
03
2022
entrez:
25
3
2022
pubmed:
26
3
2022
medline:
30
3
2022
Statut:
epublish
Résumé
The 2019 Coronavirus disease (Covid-19) has affected thousands of people worldwide. To date, vaccines appear to be the only method to prevent and reduce mortality. Four vaccinations have been outwardly approved by European Medicine Agency (EMA) in Europe: BNT162b2 (Comirnaty-BioNTech/Pfizer), mRNA-1273 (Spikevax-Moderna), ChAdOx1 (VaxzevriaAstrazeneca), and Ad26.COV2-S (Janssen-Johnson&Johnson). After vaccination, local and systemic adverse effects can occur. Cutaneous reactions like urticaria, local injection site pain, morbilliform rash have been documented after vaccination. We report four cases of oral erythema multiforme flare arising after BNT162b2 vaccination administration. All the patients denied previous erythema-like and herpetic manifestations history. Two of the reported cases (number 1 and 2) presented with both oral and cutaneous lesions, while cases 3 and 4 showed only oral manifestations. Three of the cases presented the erythema after the first vaccination dosage administration, only one case reported lesions after the second vaccination dosage administration. All the cases were treated with prednisone via oral administration and topical 0.05% clobetasol ointment. The present reports represent some of the few cases of erythema multiforme occurring as a side effect of the BNT162b2 COVID-19 vaccination. The causal role of the vaccine for the erythema multiforme has not been proven yet; nevertheless, it is not uncommon for medications to trigger this disease. The vaccine could surface a silent herpes virus infection, which would induce the erythema multiforme instead.
Sections du résumé
BACKGROUND
The 2019 Coronavirus disease (Covid-19) has affected thousands of people worldwide. To date, vaccines appear to be the only method to prevent and reduce mortality. Four vaccinations have been outwardly approved by European Medicine Agency (EMA) in Europe: BNT162b2 (Comirnaty-BioNTech/Pfizer), mRNA-1273 (Spikevax-Moderna), ChAdOx1 (VaxzevriaAstrazeneca), and Ad26.COV2-S (Janssen-Johnson&Johnson). After vaccination, local and systemic adverse effects can occur. Cutaneous reactions like urticaria, local injection site pain, morbilliform rash have been documented after vaccination.
CASES PRESENTATION
We report four cases of oral erythema multiforme flare arising after BNT162b2 vaccination administration. All the patients denied previous erythema-like and herpetic manifestations history. Two of the reported cases (number 1 and 2) presented with both oral and cutaneous lesions, while cases 3 and 4 showed only oral manifestations. Three of the cases presented the erythema after the first vaccination dosage administration, only one case reported lesions after the second vaccination dosage administration. All the cases were treated with prednisone via oral administration and topical 0.05% clobetasol ointment.
CONCLUSIONS
The present reports represent some of the few cases of erythema multiforme occurring as a side effect of the BNT162b2 COVID-19 vaccination. The causal role of the vaccine for the erythema multiforme has not been proven yet; nevertheless, it is not uncommon for medications to trigger this disease. The vaccine could surface a silent herpes virus infection, which would induce the erythema multiforme instead.
Identifiants
pubmed: 35331228
doi: 10.1186/s12903-022-02124-2
pii: 10.1186/s12903-022-02124-2
pmc: PMC8943505
doi:
Substances chimiques
COVID-19 Vaccines
0
BNT162 Vaccine
N38TVC63NU
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
90Informations de copyright
© 2022. The Author(s).
Références
Clin Exp Dermatol. 2000 Mar;25(2):167-8
pubmed: 10836849
J Am Acad Dermatol. 2021 Jul;85(1):46-55
pubmed: 33838206
Dermatol Ther. 2020 Jul;33(4):e13779
pubmed: 32506813
Clin Exp Dermatol. 2020 Oct;45(7):892-895
pubmed: 32385858
Dermatol Ther. 2021 Jan;34(1):e14717
pubmed: 33368888
Pharmacotherapy. 2006 Nov;26(11):1658-61
pubmed: 17064213
Clin Dermatol. 2021 Mar-Apr;39(2):323-328
pubmed: 34272030
Pain Pract. 2021 Nov;21(8):966-973
pubmed: 34314563
N Engl J Med. 2020 Dec 17;383(25):2427-2438
pubmed: 32991794
J Neurovirol. 2013 Aug;19(4):328-45
pubmed: 23943467
JAAD Case Rep. 2021 Jun;12:58-59
pubmed: 33937467
J Eur Acad Dermatol Venereol. 2021 Nov;35(11):e729-e730
pubmed: 34236718
Nature. 2021 Jul;595(7868):572-577
pubmed: 34044428
J Eur Acad Dermatol Venereol. 2022 Jan;36(1):e22-e24
pubmed: 34547125
Pediatr Dermatol. 2020 May;37(3):442-446
pubmed: 32445583
Clin Exp Dermatol. 2021 Oct;46(7):1325-1327
pubmed: 33914926
Sci Rep. 2021 Feb 26;11(1):4802
pubmed: 33637820
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Nat Rev Immunol. 2021 Aug;21(8):475-484
pubmed: 34211186